PGP and cancer: We found that P-gp-overexpressing KBV20C cells were highly resistant to eribulin compared with drug-sensitive KB cells (14, 36, 37), and we assumed that crizotinib could be a useful drug against eribulin-resistant cancer cells, which arise from eribulin chemotherapy.